C. D. McDermott

Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.

Charles D. McDermott, H. Zou, K. Appelt, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy of Prinomastat® (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization

Charles D. McDermott, W. Freeman, D. Bartsch, 2002, Current eye research.

Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit.

Charles D. McDermott, W. Freeman, C. Wiley, 2001, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials

Charles D. McDermott, H. Zou, S. Bender, 1999, Annals of the New York Academy of Sciences.

Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases

Charles D. McDermott, K. Appelt, C. D. McDermott, 1997, Clinical & Experimental Metastasis.

The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy

W. Freeman, K. Appelt, Lingyun Cheng, 2000 .